A Study of D4064A Administered to Patients With Recurrent or Persistent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Inclusion Criteria: * ECOG performance status of 0 or 1 * Advanced, histologically documented epithelial ovarian, primary peritoneal, or fallopian tube cancer that has progressed or relapsed during or within 12 months of treatment with a platinum-containing chemotherapy regimen, and for which no standard therapy exists * History of receiving five or fewer prior chemotherapy-containing regimens for EOC, PPC, or FTC (including primary therapy) Exclusion Criteria: * Prior treatment with chemotherapy or experimental anti-cancer agents within 4 weeks prior to Day 1 * Prior treatment with oregovomab (OvaRex(R)) or abagovomab * History or clinical evidence of central nervous system or brain metastases * Grade ≥ 2 peripheral neuropathy * History of severe allergic or anaphylactic reactions to human, humanized, chimeric, or murine monoclonal antibodies * History of clinically symptomatic liver disease, including viral or other hepatitis, history of or current alcoholism, or cirrhosis * Untreated or persistent/recurrent malignancy (other than EOC, PPC, or FTC)